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encounter any studies on disclosure of other biomarkers, including
CSF-results or neuroimaging results. Although overall disclosure
of APOE genotype seems safe, some concerns on the potential
impact remain.While developing ethics guidelines, challenges con-
cerned the development of a risk disclosure process across diverse
geographical and cultural contexts, with a heterogeneous study
population and different biomarkers. Important gaps remain in
the evidence related to national and cultural differences in percep-
tions of AD risk, and differences between genetic and biomarker-
based risk information. The focus groups highlighted the impor-
tance of providing suggestions for courses of action following
disclosure and the role of local primary and secondary care systems
in shaping the long-term impact of risk disclosure. Conclusions:
Disclosure of APOE seems relatively safe, but no data are available
on the consequences of other biomarker disclosure. The combina-
tion of a longitudinal cohort study with proof of concept clinical tri-
als poses several ethical challenges. Focus groups suggest a need
for a focus on the post-disclosure period.
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Background:Progress in developing effective treatments to prevent
cognitive impairment from AD requires clinical trials that study
cognitively normal adults. Trials such as the Anti-Amyloid in
Asymptomatic Alzheimer’s disease (A4 Study) focus on enrolling
persons with AD biomarkers, specifically, “elevated amyloid” as
seen on a PET scan. The companion LEARN cohort study is
enrolling persons whose PET scan shows “not elevated” amyloid.
The Study Of Knowledge and Reactions to Amyloid TESting
(SOKRATES) is studying a sample of A4 and LEARN participants
to understand the experience of knowing this information.Methods:
85 persons in either A4 (50) or LEARN (35) were recruited from 9
sites to participate in a telephone interview to discover how they un-
derstood and appreciated their PET scan result, who they shared it
with and how this sharing impacted on their relationships, and re-
ported changes in behaviors or perceptions of health. Follow-up In-
terviews are being performed 9 to 12 months after the initial
interview. Interviews are transcribed and analyzed by a multi-disci-
plinary team using qualitative methods that identify themes and
patterns in themes. Results:As of 1 February 2016, 50 A4 partici-
pants completed a baseline interview. The presentation will show
the results of their explanations of their amyloid PET scan result
with attention to variations in meanings of “elevated” result. Con-
clusions: Data from the SOKRATES study showing how people
interpret and reinterpret the results of their amyloid PET scan can
inform the design and translation of educational and recruitment
materials.
F4-02-04 THE ALZHEIMER’S PREVENTION INITIATIVE
(API) PROGRAM: GENETIC TESTING AND
DISCLOSURE STRATEGIES
Jessica B. Langbaum1, Jason Karlawish2, Angela R. Bradbury2,
Elisabeth MCarty Wood2, J. Scott Roberts3, Scott Kim4, Linda Patrick-
Miller5, Deborah Blacker6, Richard J. Caselli7, Gary E. Marchant8,
Doris Zallen9, Carolyn Langlois1, Trisha Walsh1, David Gordon1,
Eric M. Reiman1, Pierre N. Tariot1, 1Banner Alzheimer’s Institute, Phoenix,
AZ, USA; 2University of Pennsylvania, Philadelphia, PA, USA; 3University
of Michigan, Ann Arbor, MI, USA;
4
National Institutes of Health, Bethesda,
MD, USA;
5
Independent Consultant, Chicago, IL, USA;
6
Harvard
University, Boston, MA, USA; 7Mayo Clinic Arizona, Scottsdale, AZ, USA;
8Arizona State University, Tempe, AZ, USA; 9Virginia Tech, Blacksburg, VA,
USA. Contact e-mail: Jessica.Langbaum@bannerhealth.com
Background:TheAlzheimer’s Prevention Initiative (API) is a collab-
orative funded by the NIH, philanthropy, and industry to conduct
preclinical Alzheimer’s disease (AD) trials in people who, based
on age and genetics, are at elevated risk of developing AD symp-
toms. The API’s Generation Study is enrolling apolipoprotein E
(APOE) e4 homozygotes age 60-75. To support this and future tri-
als, API established an interdisciplinary APOE Genetic Testing
and Disclosure Committee whose aims include establishing an
APOE genetic testing program to enrich referrals to studies, known
as GeneMatch; updating APOE risk estimates; and evaluating
disclosure of genetic risk and its impact. Methods:GeneMatch is a
trial-independent program performing APOE genotyping in individ-
uals age 55-75 to enrich referrals to prevention studies. GeneMatch
uses buccal swab kits sent via mail and does not disclose APOE re-
sults to participants, either directly or inadvertently through referral
to studies. Recruiting studies, however, may ask or invite individuals
to learn their APOE results. The Generation Study includes stan-
dardized disclosure of AD risk by APOE genotype and the assess-
ment of the psychological effects of genetic disclosure. A
separate, investigator-initiated ancillary study, CONNECT 4
APOE, is examining the feasibility and efficacy of remote delivery
(phone vs. real-time videoconferencing) methods for disclosing
APOE results. Other investigator-initiated, ancillary studies
examine the impact of APOE disclosure on objective and subjective
cognitive functioning (“stereotype threat”), and its effect on fam-
ilies. Results:GeneMatch launched in 2015 and aims to enroll tens
of thousands of participants. The Generation Study launched in
November 2015; enrollment and genetic disclosure are ongoing.
The CONNECT 4 APOE, Stereotype Threat, and Impact on Fam-
ilies ancillary studies will launch in 2016. Results from these efforts
will be presented. Conclusions:GeneMatch is a key element of the
API, facilitating enrollment into a range of research studies,
including the Generation Study. Results from Generation Study’s
disclosure program and ancillary studies will help determine the ef-
fects of APOE disclosure across different modes of delivery and
enhance appreciation of the psychosocial implications of high-risk
results, with lessons for clinical practice and precision medicine,
as well as future trials in genetically enriched populations.
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